Good Mood Elixir — Mood & Serenity

1 to 3 ml per day diluted in a drink (water, juice, etc.).

• Mild/seasonal low mood : start the course at the beginning of autumn and take for 1 to 3 months depending on how you feel
• Emotional ups and downs before and/or during your period: 3 ml per day and up to 5 ml on “difficult” days. Combine with Harmonie Prémenstruelle Elixir and/or Equilibre Hormonal P
• Support during a dietary programme or to help ease sugar cravings : 2 ml around 5–6 pm, then 1 to 2 ml in the evening depending on intensity. If anxiety is significant, combine with Les Relaxantes Elixir
• Support when giving up tobacco, alcohol or another dependency : 1.5 ml three times a day as a 3 to 6 month course.
• Post-partum mood imbalance (excluding breastfeeding) : 3 ml per day and up to 5 ml on “difficult” days; do not use while breastfeeding without the advice of a healthcare professional.

Precautions for use:

Not recommended for children under 12, during pregnancy and breastfeeding, or for people on antidepressant treatment (especially SSRI type – selective serotonin reuptake inhibitors : Prozac; Deroxat, Divarius, Paxil, Zoloft, Seropram, Celexa, Seroplex, Cipralex, Priligy, Floxyfral).
Do not use for more than 6 months without the advice of a healthcare professional.

People on medication should take the elixir at least 60 minutes apart from their medication (it may reduce the hepatic metabolism of medicines)

Elixir per 3 ml, equivalent to 600 mg of dried plant (DP):

• Griffonia* – Griffonia simplicifolia – Seed 300 mg DP
• Ashwagandha* – Withania simplicifolia – Root – 120 mg DP
• St John's Wort* – Hypericum perforatum – Aerial part 120 mg DP
• Jasmine* – Jasminus communis – Aerial part 60 mg DP

Base: Organic vegetable glycerine* 55%, water

*Product from organic farming

Scientific Expertise & Academic Rigour

The formulation of our elixirs rests on a rigorous selection of active ingredients whose effectiveness and safety are validated by the international scientific literature and reference monographs (EMA, Cochrane, PubMed).

Griffonia simplicifolia (5-HTP)

• Maffei ME. (2021). 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis and Pharmacology. Molecules. A comprehensive review of serotonin biosynthesis.View the study (PubMed)
• Weinberg-Wolf H, et al. (2018). The effects of 5-hydroxytryptophan on attention and central serotonin neurochemistry. Neuropsychopharmacology.View the study (PMC)
• Jangid P. et al. (2013). Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine. Asian J Psychiatr.View the study (PubMed)

Ashwagandha (Withania somnifera)

• Pratte et al. (2014). An alternative treatment for anxiety: a systematic review of Ashwagandha. A systematic review of adaptogens.View the study (PubMed)
• Kelgane SB, et al. (2020). Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients. J Ethnopharmacol. View the study (PubMed 32818573)
• Deshpande A, et al. (2020). A randomized, double blind, placebo controlled study to evaluate the effects of ashwagandha extract on sleep quality. Sleep Med. View the study (PubMed 32540634)
• Chandrasekhar K. et al. (2012). A prospective, randomized double-blind, placebo-controlled study of ashwagandha root in reducing stress and anxiety. Indian J Psychol Med. View the study (PubMed 23439798)
• Chandrasekhar K, et al. (2012). Safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety. Indian J Psychol Med.View the study (PubMed 23439798)
• Langade D, et al. (2021). Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients. J Ethnopharmacol. A pivotal study on the regulation of rest and mental well-being.View the study (PubMed 32818573)

St John's Wort (Hypericum perforatum)

• Linde K. et al. (2008). St John's wort for major depression (Cochrane Review). Cochrane Database Syst Rev. The international reference on the subject.View the study (PubMed)
• Ng QX et al. (2017). Clinical use of Hypericum perforatum in depression: A meta-analysis. J Affect Disord.View the study (PubMed)
• Saqulain S., et al. (2025).Medicinal plants as sources of bioactive compounds: A review of Hypericum perforatum (St. John's Wort) phytochemistry and its role in mental health therapy.World Journal of Pharmaceutical and Life Sciences (WJPLS). A major review of neuroprotective mechanisms.View the study
• François D. (2010). Le millepertuis : de la plante au médicament : usages traditionnels et interactions médicamenteuses.PharmD thesis, University of Lorraine (Nancy).View the document (HAL 01738934)
• Oliveira AI, et al. (2016).Neuroprotective Activity of Hypericum perforatum and Its Major Components.Frontiers in Plant Science. A key study on antioxidant and neuroprotective properties.View the study (PubMed)